Biocon Ltd. News and Updates

Name: Latest research reports of Biocon Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 3
Author: Axis Direct

Keep track of all breaking news on Biocon Ltd. from all sources in a single place.

Load latest

Biocon Ltd.

02 Feb 2017

358.00

-0.42%

Result Update:Biocon

Hold: Biocon Ltd.

Axis Direct

Q3FY17 PAT (up 67% YoY) was 21% higher than our estimate due to 2.5x increase in licensing income (directly flows to PBT). While EBITDA margin improved to 25.7% (up 401 bps YoY), margin (ex-licensing) improved slightly (up 93 bps YoY) to 19.5%. Much-awaited Insulin facility in Malaysia is commercial..

Biocon Ltd. has an average target of 367.20 from 5 brokers.

Biocon Ltd.

31 Jan 2017

358.00

-0.42%

Break-even or marginal loss for Biocon Malaysia next year: Kiran Mazumdar-Shaw

livemint

Biocon chairperson Kiran Mazumdar-Shaw says Rs460 crore insulin supply pact with Malaysian government will de-risk Biocon's investment in setting up the plant there

Biocon Ltd. average weekly volume is high.

Biocon Ltd.

31 Jan 2017

358.00

-0.42%

Biocon Ltd Q3FY17 results comment

Results Update: Biocon Ltd.

HDFC Securities

Revenue grew by 9.7% to Rs. 1022.5 Cr in Q3FY17 when compared to the previous quarter. Also, it grew by 29.59% when compared with Q3FY16.

Biocon Ltd. average weekly volume is high.

Biocon Ltd.

27 Jan 2017

358.00

-0.42%

Biocon Q3: all eyes on pot at end of rainbow

livemint

Biocon's small molecules and biologics divisions did well, with sales up by 24% and 61% while that of branded formulations was relatively lower at 18%

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

Biocon Ltd.

27 Jan 2017

358.00

-0.42%

Biocon

Hold: Biocon Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 29% YoY to | 1044 crore (I-direct estimate: | 996 crore) mainly due to a sharp jump in licensing income and robust growth in biologics. Licensing income increased to | 79 crore from | 32 crore in Q3FY16. Biologics revenues grew 60% to | 120 crore EBITDA margins improved 354 bps YoY to 26.4% (I-direct estimate: 24.2%) mainly due to lower raw material & other expenses. Higher licensing income was also contributed to EBITDA...